Sarah Patel's Avatar
published in Blogs
Dec 29, 2022
Alzamend Neuro (ALZN, $0.51) partners with Stem Cell Institute at the University of Miami for trial of ALZN002

Alzamend Neuro (ALZN, $0.51) partners with Stem Cell Institute at the University of Miami for trial of ALZN002

Alzamend Neuro Inc .has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002.

ALZN002 is a patented immunotherapy method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to combat Alzheimer’s. On October 5, Alzamend announced the addition of healthy adult subject to its Phase IIA multiple ascending dose (“MAD”) study of AL001 in subjects with dementia related to Alzheimer’s.

“We are thrilled to add the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami to the team and have full confidence in their ability to assist us with our Phase I/IIA clinical trial of ALZN002,” stated Stephan Jackman, Chief Executive Officer of Alzamend. “We strongly believe that the ALZN002 patient-specific immunotherapeutic vaccine has the potential of fostering tolerance to treatment for safety purposes while stimulating the immune system to reduce the brain’s beta-amyloid protein burden, resulting in reduced Alzheimer’s signs and symptoms. We are advancing the process and expect to initiate this study in the first quarter of 2023.”

“We look forward to reporting topline data from the Phase IIA MAD study in the second quarter of 2023,” mentioned Mr. Jackman. “We are one step closer to providing patients, caregivers and clinicians with a major improvement over current lithium-based treatments that can help over 40 million Americans suffering from Alzheimer’s, bipolar disorder, MDD and PTSD. We look forward to completing the Phase IIA MAD study and further advancing clinical development of this promising potential therapeutic.”

Related Tickers: ALZN